N/A N=162 Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery
Thoracic Surgery
Primary: Determine the Postoperative Complications Found in Each Group — 16; 8; 56; 57 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Myeloproliferative Disorder · Urothelial Carcinoma · Cancer
Primary: Evaluate the Time to Disease Progression — 6.5; 13.9 months
Phase 2 N=45 Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Disease Response — 10; 8; 10; 2 participants
N/A N=35,921 Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)
General Safety Profile of DOTAREM
Primary: Frequency of Adverse Events — 70 Adverse Events
Phase 3 N=143 Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
Diabetes · Diabetes Mellitus, Type 2
Primary: HbA1c (Glycosylated Haemoglobin) — 7.4; 7.2 percentage of glycosylated haemoglobin
Phase 2 N=21 Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
Lung Cancer
Primary: Determine the Overall Objective Response — 6; 13 participants
N/A N=663 Educational Intervention for Knee Pain
Osteoarthritis
Primary: Change in Willingness. — 1; 1; 1; 1 participants — p=<0.05
Phase 2 N=63 Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
Breast Cancer
Primary: Overall Objective Response — 0; 0; 8; 0 participants
Phase 2 N=237 Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Leukemia
Primary: Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to…
Phase 3 N=1,066 Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Lower Urinary Tract Symptoms · Benign Prostatic Hyperplasia
Primary: Number of Participants With Adverse Events (AEs) — 499; 255; 12; 69 participants
Phase 2 N=32 Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Maximum Tolerated Dose — 1 mCi/kg
Phase 4 N=1,469 ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) — 65; 76 percentage of participants — p=<.0001
Phase 3 N=111 International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia
Hyponatremia
Primary: Participants With Adverse Events (AEs) — 105; 76; 73; 19 participants
Phase 3 N=530 A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
Gastric Ulcer
Primary: Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg — 10; 23 participants — p=0.020
Phase 2 N=250 A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Crohn's Disease
Primary: The Crohn's Disease Activity Index (CDAI)-70 Response Rate at Week 8 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg — 30.6; 35.0; 49.3…